# **Appendix 4E**

## Preliminary final report for the financial year ended 30 June 2023

Name of entity

VECTUS BIOSYSTEMS LIMITED ABN: 54 117 526 137

Reporting period: 30 June 2023
Previous period: 30 June 2022
Results for announcement to the market

				AUD
Revenues from ordinary activities Loss from ordinary activities	up	4.2%	to	1,354,535
after tax attributable to	down	13.6%	to	(3,448,860)
Loss for the period attributable to owners of	down	13.6%	to	(3,448,860)
Vectus Biosystems Limited				

Dividends (distributions)	Amount per security	Franked amount per y security	
Final dividend	Nil ¢	Nil ¢	
Previous corresponding period	Nil ¢	Nil ¢	

#### Brief explanation of the above

The Group has incurred an operating loss of \$3,448,860 for the year ended 30 June 2023 (2022: Operating loss of \$3,993,775) and the net equity has improved from a deficit of \$3,533,995 as at 30 June 2022 to a surplus of \$3,523,504 as at 30 June 2023. The operating cash burn rate for the year ended 30 June 2023 was \$2,352,742 (2022: \$4,441,231). The cash balance as at 30 June 2023 was \$2,950,956.

This Appendix 4E should be read in conjunction with the Half Year Financial Report of the Group as at 31 December 2022. It is also recommended that the Appendix 4E be considered together with any public announcements made by the Group since commencement of the 2022-23 financial year in accordance with the continuous disclosure obligations arising under the *Corporations Act 2001*.

NTA backing	30-Jun-23	30-Jun-22	
	cents	cents	
Net tangible asset backing per ordinary share	6.62	(5.96)	

#### **Events occurring after Balance Date**

No matter or circumstance has arisen since 30 June 2023 that has significantly affected or may significantly affect the consolidated entities' operations, the results of these operations, or the consolidated entities' state of affairs in future financial years.

#### Details of entities over which control has been gained or lost during the period

Not Applicable

### Foreign Entities details

Not Applicable

#### **Dividends**

No dividends were paid or proposed during the financial year.

## **Audit or Review details**

This report is based on accounts which have been audited.

Sign here: (Director/Company Secretary)

Date: 30 August 2023